Tien Laboratory

Researcher holding a bottle of liquid in the lab


We actively pursue new drug combination clinical trials for brain tumor patients. The newly developed Phase 0 platform combined with precision medicine allows us to understand pharmacodynamic endpoints in the tumor, providing insights for overcoming the brain-blood barrier and drug target inhibition. The newly established Ivy Pharmacodynamics Core is CLIA-certified where our assays and biosamples are validated and carefully monitored to provide trustworthy clinical quality results. Our long-term goal is to understand cellular and molecular mechanisms underlying glioma formation, thereby speeding current drug discovery processes for glioma treatment in patients.

Current Research

Some of the ongoing projects are focused on addressing following:

  1. Biomarker and genomic analyses with next generation sequencing (IvySeq) to provide personalized enrollment recommendation.
  2. Pharmacodynamic analysis to assess treatment response and target modulation.
  3. Understanding resistance mechanisms of targeted inhibitors underlying disease progression.

Lab Members

Anita DeSantis hexagon cutoutRead Bio

Anita DeSantisResearch Technician

Jennifer MolloyRead Bio

Jennifer MolloyResearch Technician

Alexis RatliffRead Bio

Alexis RatliffResearch Technician

Generic Woman Avatar OutlineRead Bio

Casaundra KrobResearch Technician










Postdoctoral Fellow-PD

We are currently recruiting a highly motivated and driven Postdoctoral Fellow, preferably a recent graduate (Ph.D., M.D., DVM), to join our PD Laboratory team. A background in the field of Cancer Biology, Genetics, Pharmacology, Neurobiology, or Molecular and Cellular Biology will be considered. Prior experience in conducting drug treatment studies and knowledge of signal transduction pathways is preferred.

Research Technician I – PD

The Ivy Brain Tumor Center is currently recruiting a highly motivated and driven research technician, (B.S. or M.S.) to join our pharmacodynamics lab focusing on cutting edge Phase 0/II clinical trials for glioblastoma at BNI. Candidates with experience in preclinical studies are desirable. Prior experience in conducting molecular biology or genetic assays and knowledge of signal transduction and oncogenic pathways is preferred.